Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed)
ID: 358158Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358158

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-006.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed)" aimed at supporting research into the mechanisms of action of combined vaccine adjuvants. This initiative seeks to enhance the understanding of how multiple adjuvants work together to improve immune responses, particularly for vulnerable populations such as neonates and older adults. The NIH plans to allocate approximately $2.56 million to fund 4-6 awards, with annual budget requests expected to be under $500,000, and applications are due by June 11, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-25-006-Full-Announcement.html
    RFA-AI-25-006.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued a funding opportunity titled "Molecular Mechanisms of Combination Adjuvants" (RFA-AI-25-006). The purpose is to support research into the mechanisms of action of combined vaccine adjuvants, which are crucial for enhancing immune responses in vaccines. This initiative aims to advance the rational design of vaccines, particularly for populations like neonates and older adults. Eligible applicants include various institutions and organizations such as higher education institutions, nonprofits, local governments, and foreign entities. Budget requests are expected to be under $500,000 annually, with NIAID planning to allocate approximately $2.56 million to fund 4-6 awards beginning in FY 2026. The application process includes specific guidelines on collaboration, data management, and adherence to NIH policies. Applications are due by June 11, 2025, with funding priorities focused on innovative research addressing significant knowledge gaps in vaccine adjuvants, further supporting public health initiatives. The initiative acknowledges the growing need for advanced adjuvant strategies to enhance vaccine efficacy and broaden immune responses.
    Similar Opportunities
    Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" (FO No. PAR-24-112) aimed at enhancing research on innate immune memory. This initiative seeks to support studies that identify biomarkers of trained immunity, elucidate underlying molecular mechanisms, and assess the implications for immune system function, particularly in relation to vaccines, infections, and autoimmune or allergic diseases. The funding is crucial for advancing immunological research with significant public health implications, and applications are due by June 5, 2024, and October 5, 2024. Interested applicants can find more information and submit their proposals via Grants.gov, and for inquiries, they may contact NIH Grants Information at grantsinfo@nih.gov.
    Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)," aimed at advancing research in mucosal immunology. This initiative seeks to establish a cooperative research group focused on understanding immune mechanisms and regulation at mucosal surfaces across various tracts, including respiratory, gastrointestinal, and urogenital systems. The program is significant for fostering innovative approaches and technologies to tackle complex questions in this field. The estimated total funding for this program is $3 million, with approximately five awards expected to be made. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for the application process, which will open following the publication of the Notice of Funding Opportunity (NOFO) expected on July 3, 2025. For further inquiries, potential applicants can contact Dr. Deborah L. Hodge at hodged@mail.nih.gov or by phone at 240-551-3037.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Impact of Initial Influenza Exposure on Immunity in Infants
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Impact of Initial Influenza Exposure on Immunity in Infants," aimed at advancing research on how influenza infections and vaccinations affect infant and childhood immunity. The initiative seeks to establish and characterize longitudinal cohorts of infants and mother-infant dyads to investigate the influence of initial exposure to influenza antigens on immune responses to subsequent infections and vaccinations. This research is critical for developing durable and broadly protective influenza vaccines. The estimated total program funding is $10 million, with three awards expected, and interested applicants can reach out to Dr. Michelle M. Arnold at michelle.arnold@nih.gov or by phone at 301-761-7324. Key deadlines include an estimated synopsis close date of February 11, 2026, and an estimated award date of December 1, 2026.
    Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Immune System Development and Ontogeny" under the R01 Clinical Trial Optional grant program. This initiative aims to investigate the mechanisms of early immune development in children, particularly focusing on those with in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART), and includes research on maternal and paternal immune statuses, immune cell development, and environmental influences. The program is significant for advancing laboratory research and clinical trials that enhance understanding of immune maturation in neonates and children. Eligible applicants can receive up to $400,000 per year for a maximum project duration of four years, with applications opening on April 7, 2025, and closing on January 8, 2029. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity for the establishment of an Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC). This initiative aims to enhance the NIH's mission by providing comprehensive support for clinical study development, regulatory compliance, site monitoring, and biostatistical assistance for clinical trials focused on autoimmune diseases and related areas. The AD-SCCC will play a crucial role in advancing research and collaboration within the field, with an estimated total program funding of $8 million and the expectation of one award. Interested applicants can reach out to Dr. Jeffrey Rice at jeffrey.rice@nih.gov or by phone at 240-627-3552 for further details, with proposals due by June 4, 2026, and the anticipated award date set for March 1, 2027.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)" aimed at supporting the development of broadly protective vaccines for hepatitis C virus (HCV). This initiative seeks to establish a consortium of Research Centers that will focus on the design, optimization, evaluation, and advancement of vaccine candidates into clinical trials, encouraging collaborative investigations among experts in HCV vaccine development. The estimated total program funding is $8.3 million, with four awards expected, and interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on July 7, 2025. For further inquiries, potential applicants can contact Dr. Rajeev Gautam at rajeev.gautam@nih.gov or by phone at 301-761-5347.
    HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "HIV Vaccine Research and Design (HIVRAD) Program," aimed at advancing research for an effective prophylactic vaccine against HIV/AIDS. This grant encourages multi-disciplinary projects that address significant scientific questions in vaccine discovery, including preclinical evaluations in non-human primate models, while explicitly prohibiting clinical trials. The NIH plans to fund 1-2 awards totaling approximately $5 million for fiscal year 2025, with applications due by March 13, 2024, and an open submission date starting February 13, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application guidelines available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.